Top

Published in:

01-06-2019 | Amyotrophic Lateral Sclerosis | Original Communication

Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort study

Authors: Toshio Shimizu, Yuki Nakayama, Chiharu Matsuda, Michiko Haraguchi, Kota Bokuda, Kazuko Ishikawa-Takata, Akihiro Kawata, Eiji Isozaki

Published in: Journal of Neurology | Issue 6/2019

Abstract

Background

Body weight reduction after disease onset is an independent predictor of survival in amyotrophic lateral sclerosis (ALS), but significance of weight variation after diagnosis remains to be established.

Objective

To investigate weight variation after diagnosis and its prognostic significance in patients with ALS as a prospective cohort study.

Methods

Seventy-nine patients with ALS were enrolled in this study. At the time of diagnosis and about 1 year later, we evaluated the following parameters: age, sex, onset age, onset region, body mass index (BMI) and premorbid BMI, forced vital capacity and the revised ALS functional rating scale. Annual BMI decline rates (∆BMI) from onset to diagnosis and from diagnosis to about 1 year later were calculated. Patients were followed to the endpoints (death or tracheostomy), and the relationships between ∆BMIs and survival were investigated.

Results

Patients with post-diagnostic ∆BMI ≥ 2.0 kg/m²/year showed shorter survival length than those with < 2.0 kg/m²/year (log-rank test, p < 0.0001), and multivariate analysis using the Cox model revealed post-diagnostic ∆BMI as an independent prognostic factor. No correlation was identified between pre- and post-diagnostic ∆BMIs. Female patients with post-diagnostic ∆BMI < pre-diagnostic ∆BMI showed longer survival than those with the opposite ∆BMI trend (log-rank test, p = 0.0147). Female patients with post-diagnostic weight increase showed longer survival than those with weight decrease (log-rank test, p = 0.0228).

Conclusion

Body weight changes after diagnosis strongly predicts survival in ALS, and weight gain after diagnosis may improve survival prognosis, particularly in female ALS patients.

Dupuis L, Pradat PF, Ludolph AC, Loeffler JP (2011) Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 10:75–82. https://doi.org/10.1016/S1474-4422(10)70224-6 CrossRefPubMed

Holm T, Maier A, Wicks P et al (2013) Severe loss of appetite in amyotrophic lateral sclerosis patients: online self-assessment study. Interact J Med Res 2:e8. https://doi.org/10.2196/ijmr.2463 CrossRefPubMedPubMedCentral

Shimizu T (2013) Sympathetic hyperactivity and sympathovagal imbalance in amyotrophic lateral sclerosis. Eur Neurol Rev 8:46–50. https://doi.org/10.17925/ENR.2013.08.01.46 CrossRef

Bouteloup C, Desport JC, Clavelou P et al (2009) Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol 256:1236–1242. https://doi.org/10.1007/s00415-009-5100-z CrossRefPubMed

Kasarskis EJ, Mendiondo MS, Matthews DE et al (2014) Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am J Clin Nutr 99:792–803. https://doi.org/10.3945/ajcn.113.069997 CrossRefPubMedPubMedCentral

Shimizu T, Ishikawa-Takata K, Sakata A et al (2017) The measurement and estimation of total energy expenditure in Japanese patients with ALS: a doubly labelled water method study. Amyotroph Lateral Scler Frontotemporal Degener 18:37–45. https://doi.org/10.1080/21678421.2016.1245756 CrossRefPubMed

Steyn FJ, Ioannides ZA, van Eijk RPA et al (2018) Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry 89:1016–1023. https://doi.org/10.1136/jnnp-2017-317887 CrossRefPubMed

Desport JC, Preux PM, Truong TC et al (1999) Nutritional status is a prognostic factor for survival in ALS patients. Neurology 53:1059–1063CrossRefPubMed

Marin B, Desport JC, Kajeu P et al (2011) Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 82:628–634. https://doi.org/10.1136/jnnp.2010.211474 CrossRefPubMed

10.

Paganoni S, Deng J, Jaffa M et al (2011) Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 44:20–24. https://doi.org/10.1002/mus.22114 CrossRefPubMedPubMedCentral

11.

Shimizu T, Nagaoka U, Nakayama Y et al (2012) Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler 13:363–366. https://doi.org/10.3109/17482968.2012.678366 CrossRefPubMed

12.

McDonnell E, Schoenfeld D, Paganoni S, Atassi N (2017) Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis. Neurology 89:1483–1489. https://doi.org/10.1212/WNL.0000000000004534 CrossRefPubMedPubMedCentral

13.

Miller RG, Jackson CE, Kasarskis EJ et al (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1218–1226. https://doi.org/10.1212/WNL.0b013e3181bc0141 CrossRefPubMedPubMedCentral

14.

Wills AM, Hubbard J, Macklin EA et al (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 383:2065–2072. https://doi.org/10.1016/S0140-6736(14)60222-1 CrossRefPubMedPubMedCentral

15.

Dupuis L, Oudart H, Rene F et al (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA 101:11159–11164. https://doi.org/10.1073/pnas.0402026101 CrossRefPubMedPubMedCentral

16.

Dorst J, Dupuis L, Petri S et al (2015) Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. J Neurol 262:849–858. https://doi.org/10.1007/s00415-015-7646-2 CrossRefPubMed

17.

Fasano A, Fini N, Ferraro D et al (2017) Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. Amyotroph Lateral Scler Frontotemporal Degener 18:233–242. https://doi.org/10.1080/21678421.2016.1270325 CrossRefPubMed

18.

Heritier AC, Janssens JP, Adler D et al (2015) Should patients with ALS gain weight during their follow-up? Nutrition 31:1368–1371. https://doi.org/10.1016/j.nut.2015.06.005 CrossRefPubMed

19.

Kellogg J, Bottman L, Arra EJ et al (2018) Nutrition management methods effective in increasing weight, survival time and functional status in ALS patients: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener 19:7–11. https://doi.org/10.1080/21678421.2017.1360355 CrossRefPubMed

20.

Shimizu T, Bokuda K, Kimura H et al (2018) Sensory cortex hyperexcitability predicts short survival in amyotrophic lateral sclerosis. Neurology 90:e1578–e1587. https://doi.org/10.1212/WNL.0000000000005424 CrossRefPubMed

21.

Brooks BR, Miller RG, Swash M et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299CrossRefPubMed

22.

de Carvalho M, Dengler R, Eisen A et al (2008) Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 119:497–503. https://doi.org/10.1016/j.clinph.2007.09.143 CrossRefPubMed

23.

Kim WK, Liu X, Sandner J et al (2009) Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 73:1686–1692. https://doi.org/10.1212/WNL.0b013e3181c1dea3 CrossRefPubMedPubMedCentral

24.

Cedarbaum JM, Stambler N, Malta E et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13–21CrossRefPubMed

25.

Logroscino G, Traynor BJ, Hardiman O et al (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79:6–11. https://doi.org/10.1136/jnnp.2006.104828 CrossRefPubMed

26.

Manjaly ZR, Scott KM, Abhinav K et al (2010) The sex ratio in amyotrophic lateral sclerosis: a population based study. Amyotroph Lateral Scler 11:439–442. https://doi.org/10.3109/17482961003610853 CrossRefPubMedPubMedCentral

27.

de Jong S, Huisman M, Sutedja N et al L (2013) Endogenous female reproductive hormones and the risk of amyotrophic lateral sclerosis. J Neurol 260:507–512. https://doi.org/10.1007/s00415-012-6665-5 CrossRefPubMed

28.

Mauvais-Jarvis F, Clegg DJ, Hevener AL (2013) The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 34:309–338. https://doi.org/10.1210/er.2012-1055 CrossRefPubMedPubMedCentral

29.

Vercruysse P, Sinniger J, El Oussini H et al (2016) Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain 139:1106–1122. https://doi.org/10.1093/brain/aww004 CrossRefPubMed

30.

Vercruysse P, Vieau D, Blum D et al (2018) Hypothalamic alterations in neurodegenerative diseases and their relation to abnormal energy metabolism. Front Mol Neurosci 11:2. https://doi.org/10.3389/fnmol.2018.00002 CrossRefPubMedPubMedCentral

31.

Watanabe H, Atsuta N, Hirakawa A et al (2016) A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J Neurol Neurosurg Psychiatry 87:851–858. https://doi.org/10.1136/jnnp-2015-311541 CrossRefPubMed

32.

Jesus P, Fayemendy P, Nicol M et al (2018) Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol 25:97–104. https://doi.org/10.1111/ene.13468 CrossRefPubMed

33.

Gorges M, Vercruysse P, Muller HP et al (2017) Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 88:1033–1041. https://doi.org/10.1136/jnnp-2017-315795 CrossRefPubMed

34.

Scherz B, Rabl R, Flunkert S et al (2018) mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms. PLoS One 13:e0197674. https://doi.org/10.1371/journal.pone.0197674 CrossRefPubMedPubMedCentral

35.

Cykowski MD, Takei H, Schulz PE et al (2014) TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis. Acta Neuropathol Commun 2:171. https://doi.org/10.1186/s40478-014-0171-1 CrossRefPubMedPubMedCentral

36.

Ahmed RM, Caga J, Devenney E et al (2016) Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. J Neurol 263:1593–1603. https://doi.org/10.1007/s00415-016-8168-2 CrossRefPubMed

37.

Ahmed RM, Irish M, Piguet O et al (2016) Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurol 15:332–342. https://doi.org/10.1016/S1474-4422(15)00380-4 CrossRefPubMed

38.

Jesus P, Marin B, Fayemendy P et al (2018) Resting energy expenditure equations in amyotrophic lateral sclerosis, creation of an ALS-specific equation. Clin Nutr https://doi.org/10.1016/j.clnu.2018.08.014 (early online)CrossRefPubMed

Title: Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort study
Authors: Toshio Shimizu
Yuki Nakayama
Chiharu Matsuda
Michiko Haraguchi
Kota Bokuda
Kazuko Ishikawa-Takata
Akihiro Kawata
Eiji Isozaki
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keyword: Amyotrophic Lateral Sclerosis
Published in: Journal of Neurology / Issue 6/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09276-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort study

Abstract

Background

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2019

Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis

Prognostic factors in ALS: a comparison between Germany and China

Non-motor symptoms in Huntington’s disease: a comparative study with Parkinson’s disease

A cluster of disseminated small cortical lesions in MELAS: its distinctive clinical and neuroimaging features

Congenital myopathies are mainly associated with a mild cardiac phenotype

Risk factors for in-hospital and follow-up mortality after childhood arterial ischemic stroke